



# 炎症性肠病 研究进展

Advances on  
Inflammatory  
Bowel Disease

主编 欧阳钦  
副主编 张正 万学红

四川科学技术出版社

112372

*Advances on Inflammatory Bowel Disease*

# 炎症性肠病研究进展

主 编 欧阳钦

副主编 张 正 万学红

编 委

C.Fiocchi

C.Owyang

邓长生

徐富星

姜若兰

张 正

谢 艳

W.F.Stenson

潘国宗

吴小平

刘彤华

沈谋绩

万学红

L.R.Sutherland

吴开春

凌奇荷

官恩聪

郑家驹

温忠慧

K.Kusugami

夏 冰

刘新光

胡品津

欧阳钦

胡仁伟



四川科学技术出版社

解放军医学图书馆(书)



\*00210918\*

## 图书在版编目(CIP)数据

炎症性肠病研究进展/欧阳钦著. - 成都:四川科学技术出版社, 2000.10

ISBN 7-5364-4597-0

0

I. 炎… II. 欧… III. 炎症-肠疾病-研究-进展  
IV. R574

中国版本图书馆 CIP 数据核字(2000)第 72385 号

2000.10

## 炎症性肠病研究进展

主 编 欧阳钦  
责任编辑 康利华  
封面设计 李 庆  
版面设计 康永光  
责任校对 戴林等  
责任出版 周红君  
出版发行 四川科学技术出版社  
成都盐道街 3 号 邮政编码 610012  
开 本 787mm × 1092mm 1/16  
印张 17.75 字数 410 千  
印 刷 成都宏明印刷厂  
版 次 2000 年 10 月成都第一版  
印 次 2000 年 10 月成都第一次印刷  
印 数 1-2 000 册  
定 价 40.00 元  
ISBN 7-5364-4597-0/R·1032

■ 版权所有·翻印必究 ■

■ 本书如有缺页、破损、装订错误,请寄回印刷厂调换。

■ 如需购本书,请与本社邮购组联系。

地址/成都盐道街 3 号

邮政编码/610012

## 序

炎症性肠病 (IBD) 在西方国家已是常见病和多发病, 近 30 年来, 溃疡性结肠炎 (UC) 的发病率维持不变, 而 Crohn 病 (CD) 的发病率则逐渐上升。消化科医师对 IBD 的熟悉程度并不亚于上消化道疾病。近年, 国外对 IBD 病因及发病机制的研究也十分活跃, 动物模型、体外实验研究、临床观察和循证医学证据表明, 环境、遗传及免疫紊乱因素均可能参与 IBD 的发病。因此, 已出现了不少针对免疫调节机制的新型免疫疗法, 如使用 TNF- $\alpha$  单抗治疗 CD 等, 取得了满意疗效。我国过去一直认为 IBD 较少见, 而对其不够重视, 最近 20 年来这一现象虽有所改变, 但因研究起点低、深度不够, 且治疗试验文章较少随机对照, 因而需在临床科研方法学上加以提高。

华西医科大学附属第一医院以欧阳钦教授为首的消化内科多年从事 IBD 研究, 尤其对 IBD 的病因及发病机制等进行了基础与临床相结合的研究。近年来, 该院在欧阳钦教授的领导下, 其研究小组在动物模型及细胞免疫研究方面取得了令人瞩目的成绩, 研究方向明确, 且有一定深度, 是我国 IBD 研究的楷模。

这次华西医科大学附属第一医院受中华医学会消化病学分会委托, 承办全国炎症性肠病学术会议。组委会特邀 5 位国外知名学者和 13 位国内专家进行讲学, 并将专家发言稿与全国各地来稿汇编成册, 以期国内消化科医师能对当前国内外 IBD 研究的最新动态有一全面认识 and 了解。跨世纪中国的 IBD 发病率会逐步增高, 并将掀起研究 IBD 的热潮。本次会议将作为一个里程碑, 标志着国内 IBD 研究的新起点与新高潮。

常树东

2000 年 9 月

## 前言

诚如多年来我们一直呼吁的那样,炎症性肠病的研究在我国尚处于初始阶段。近年来各地报告病例迭有增加,引起同行的注意。预计随着生活水平的提高、生活方式的改变以及严重的肠道感染的控制,这类疾病的患病率将不断增加。有学者预言,新世纪到来之时也是我国炎症性肠病研究高潮兴起之日。事实上,从近年来的动向,我们已经看到了这一发展的趋势。不少国内同行在此领域的研究,无论是基础还是临床都已取得一定成绩,可谓硕果累累,前景喜人。

在此大好时机,我们接受中华医学会消化病学分会委托,承办全国炎症性肠病学术会议。经过近一年的筹备,邀请国内外专家撰稿,组织大会征文,约请部分研究工作者完成译文和综述。经过大家共同的努力,此次会议资料内容丰富而新颖,至少部分反映了当前国内外研究的进展,对今后基础研究和临床实践均有一定借鉴意义,故决定汇编成册,正式出版,以备同道参阅。

全书包括五章,依次为国外专家讲演提纲、国内专家专题讲座、大会论文摘要、综述与译文、国内外 IBD 诊断标准和治疗指南摘录,以及华西医科大学的 IBD 诊断标准和处理指南等,希望能成为同道的一本专题参考书,对科研起到开阔思路、承前启后的作用,对临床诊治起到规范和指南的作用,使我国炎症性肠病的研究在此基础上大步快走,赶超世界研究水平。

本书在编写过程中,得到了中华医学会消化病学分会专家们的大力支持,得到四川科技出版社的热情帮助,特此致以深深的谢意。

由于编纂时间仓促,加之水平有限,谬误之处在所难免,望同道们在阅读中批评指正,提出宝贵意见。

华西医大附一院

欧旧秋

# 目录

## 第一章 国外专家讲演提纲

1. Causes and Mechanisms of Inflammatory Bowel Disease .....	( 1 )
炎症性肠病的病因和发病机制 .....	( 6 )
2. Cyclooxygenase-2 (COX-2) in the Gastrointestinal Tract .....	( 9 )
COX-2 在胃肠道的表达及其作用 .....	(12)
3. Inflammatory Bowel Disease, Differential Diagnosis and Pathology .....	(13)
炎症性肠病的鉴别诊断和病理学 .....	(17)
4. The Indispensable Ordeal: Controlled Trials in IBD .....	(19)
不可缺少的严峻考验: 炎症性肠病对照试验 .....	(22)
5. Management of Ulcerative Colitis .....	(24)
溃疡性结肠炎的治疗 .....	(28)
6. Cyclosporine therapy for patients with steroid-resistant u .....	(31)
环孢素治疗类固醇抵抗性溃疡性结肠炎: 一种强有力的治疗方法 .....	(34)
7. Intestinal Inflammation and Visceral Hypersensitivity .....	(36)
肠道炎症和内脏高敏反应 .....	(39)

## 第二章 国内专家专题讲座

1. 缩小与国际的差距 加强炎症性肠病的研究 .....	(41)
2. 巨噬细胞与炎症性肠病 .....	(43)
3. 炎症性肠病的遗传易感性问题 .....	(44)
4. DSS 结肠炎模型及有关进展 .....	(48)
5. 抗中性粒细胞胞浆抗体与炎症性肠病的关系 .....	(49)
6. 炎症性肠病结肠镜检查的评价 .....	(52)
7. 炎症性肠病粘膜活检建议诊断要点 .....	(55)
8. 特发性炎症性肠病的病理诊断 .....	(56)
9. 炎症性肠病的粘膜活检诊断 .....	(58)
10. 小肠灌肠对小肠炎症性病变的诊断 .....	(62)
11. Crohn 病的诊断 .....	(64)

12. 炎症性肠病的治疗进展 ..... (66)
13. 炎症性肠病的营养问题 ..... (70)

### 第三章 大会论文摘要

1. 炎症性肠病大鼠小肠肠段 6 个细胞因子表达的研究 ..... (75)
2. 溃疡性结肠炎患者肠粘膜及外周血中淋巴细胞表型与功能研究 ..... (76)
3. 白细胞介素-17 介导溃疡性结肠炎的炎症反应 ..... (78)
4. TNBS 结肠炎的建立及丁酸钠疗效观察 ..... (79)
5. 表皮生长因子与谷氨酰胺对大鼠乙酸性结肠炎的影响 ..... (80)
6. 肿瘤坏死因子 TNF- $\alpha$ mRNA 在溃疡性结肠炎中的表达及作用研究 ..... (81)
7. Fas/FasL 介导的结肠上皮细胞凋亡在溃疡性结肠炎中的作用初探 ..... (82)
8. M30 和 Ki-67 检测溃疡性结肠炎肠上皮细胞的凋亡和增殖 ..... (84)
9. 溃疡性结肠炎 IL-1 $\beta$ 、IL-1ra 和 IL-4 基因多态性研究 ..... (85)
10. 溃疡性结肠炎 ANCA 和 HLA-DR 基因分型的研究 ..... (86)
11. 淋巴毒素  $\alpha$ AspH<sub>1</sub> 基因型和白介素 1 受体拮抗剂基因型与溃疡性结肠炎遗传易感性的相关研究 ..... (87)
12. 活检对溃疡性结肠炎诊断价值的研究 ..... (88)
13. 尼古丁通过增加 IFN- $\gamma$  生成加剧 DSS 诱导小鼠实验性肠炎 ..... (89)
14. 内镜活检对 Crohn 病的诊断价值 ..... (90)
15. 肠结核的内镜活检诊断及其与 Crohn 病的鉴别诊断 ..... (91)
16. 疾病活动指数 (DAI) 在炎症性肠病诊断中的应用 ..... (92)
17. 成都市 198 例溃疡性结肠炎住院病例回顾 ..... (94)
18. 雷公藤多甙治疗大鼠炎症性肠病的作用观察 ..... (95)
19. 危重型溃疡性结肠炎的诊治与转归 ..... (96)
20. 我国溃疡性结肠炎治疗性试验的研究现状 ..... (97)
21. 抗 TNF $\alpha$  抗体治疗 Crohn 病的疗效评价 ..... (99)
22. 艾迪莎治疗炎症性肠病的疗效及安全性 ..... (100)
23. 溃疡性结肠炎免疫指标检测的临床意义——附 30 例检查结果分析 ..... (101)
24. 溃疡性结肠炎患者血小板功能的变化 ..... (102)
25. 溃疡性结肠炎临床与内镜表现的相关性分析 ..... (103)
26. 炎症性肠病的诊断再评价及预后 ..... (105)
27. 溃疡性结肠炎与抗中性粒细胞胞浆抗体 ..... (106)
28. 抗中性粒细胞胞浆抗体对维吾尔族 ..... (107)
29. 炎症性肠病中的抗中性粒细胞胞浆抗体 ..... (108)
30. 炎症性肠病 T 淋巴细胞亚群的改变及临床意义 ..... (109)
31. M 细胞损害——Crohn 病的早期病理改变? ..... (110)
32. 溃疡性结肠炎中 PGE<sub>2</sub> 含量测定的临床意义 ..... (111)
33. 溃疡性结肠炎病人血清 G-CSF 和 CRP 水平的研究 ..... (113)

34. 炎症性肠病患者肠粘膜表达白细胞介素 18 的研究 .....	(114)
35. 溃疡性结肠炎患者血清中抗 Cyclophilin A (CA) 抗体的测定 .....	(115)
36. IL-1 $\beta$ 与溃疡性结肠炎不同阶段相关性研究 .....	(117)
37. 溃疡性结肠炎患者血浆胃动素水平的研究 .....	(117)
38. 锌对实验性结肠炎大鼠的作用 .....	(118)
39. 上海部分地区结肠镜检查中溃疡性结肠炎的调查分析 .....	(120)
40. 75 例溃疡性结肠炎的活检标本病理分析 .....	(121)
41. 溃疡性结肠炎肠镜活检的病理诊断 .....	(122)
42. 35 例溃疡性结肠炎的误诊分析 .....	(124)
43. Crohn 病、肠结核和原发性肠道淋巴瘤的临床对比分析 .....	(125)
44. Crohn 病不典型临床表现与有关因素 .....	(127)
45. 11 例 Crohn 病的临床诊治及误诊原因分析 .....	(127)
46. 误以急腹症行急诊手术的 7 例 Crohn 病与同期 .....	(128)
47. 溃疡性结肠炎数据库的建立和使用 .....	(129)
48. 溃疡性结肠炎的内镜下表现及治疗后转归——附 227 例报告 .....	(131)
49. 103 例溃疡性结肠炎的内镜和临床分析 .....	(132)
50. NSAIDS 所致肠道损害——附 7 例报道及文献复习 .....	(134)
51. 全结肠镜检查对溃疡性结肠炎的诊断价值 .....	(135)
52. 全结肠镜诊断炎症性肠病的分析 .....	(136)
53. 临床表现不典型 Crohn 病的内镜与病理组织特点 .....	(138)
54. 溃疡性结肠炎 88 例临床和内镜分析 .....	(138)
55. 115 例炎症性肠病临床分析 .....	(140)
56. 126 例溃疡性结肠炎住院病人临床分析 .....	(142)
57. 溃疡性结肠炎 158 例分析 .....	(143)
58. 从我院住院病人看溃疡性结肠炎的发病趋势 .....	(144)
59. 溃疡性结肠炎病人的肠外表现及并发症 .....	(146)
60. 溃疡性结肠炎早期诊断的探讨 .....	(147)
61. 动态技术对小肠恶性淋巴瘤、肠结核、Crohn 病的检查与诊断的作用 .....	(148)
62. 溃疡性结肠炎 102 例结肠镜检查及临床分析 .....	(149)
63. 内镜下溃疡性结肠炎 66 例临床分析 .....	(150)
64. 结肠镜检出 49 例溃疡性结肠炎临床资料分析 .....	(151)
65. 104 例溃疡性结肠炎的临床与内镜诊断分析 .....	(153)
66. Crohn 病临床与病理诊断的比较——附 14 例分析 .....	(154)
67. 克隆病 18 例临床分析 .....	(155)
68. 酪酸菌对大鼠 DSS 结肠炎的疗效观察 .....	(156)
69. 溃疡性结肠炎患者结肠电异常及针刺调整作用 .....	(157)



70. 氢化可的松与柳氮磺胺吡啶局部应用治疗溃疡性直、乙状结肠炎的对比研究 ..... (159)
71. 重症溃疡性结肠炎内科综合治疗 ..... (160)
72. 五氨基水杨酸灌肠剂治疗远端溃疡性结肠炎临床体会 ..... (161)
73. 艾迪莎治疗溃疡性结肠炎的疗效观察 ..... (162)
74. 艾迪莎治疗溃疡性结肠炎的临床疗效 ..... (163)
75. 柳氮磺胺吡啶治疗溃疡性结肠炎 24 例 ..... (165)
76. 替硝唑、地塞米松保留灌肠治疗溃疡性结肠炎 ..... (166)
77. 大剂量转移因子治疗顽固性溃疡性结肠炎 ..... (167)
78. 思密达治疗溃疡性结肠炎 36 例临床观察 ..... (168)
79. 麦滋林-S 及庆大霉素保留灌肠治疗溃疡性结肠炎疗效观察 ..... (169)
80. 中西医结合治疗慢性非特异性溃疡性结肠炎临床观察 ..... (170)
81. 锡类散与西药灌肠治疗溃疡性结肠炎的疗效 ..... (172)
82. 加压保留灌肠治疗右半结肠溃疡性结肠炎 58 例观察 ..... (173)
83. 苦参合剂直肠滴入法治疗溃疡性结肠炎 28 例 ..... (174)
84. 中药二步灌肠法治疗溃疡性结肠炎 51 例 ..... (176)
85. 中西医结合治疗溃疡性结肠炎 18 例临床分析 ..... (177)
86. 肛周 Crohn 病——附 3 例报告 ..... (178)
87. 食道小肠和结肠 Crohn 病 1 例 ..... (179)
- 列题
88. 溃疡性结肠炎组织 IL-8 水平、微量白蛋白与溃疡性结肠炎的关系及意义 ..... (180)
89. 溃疡性结肠炎患者外周血 T 淋巴细胞亚群变化的探讨 ..... (180)
90. 山西地区炎症性肠病流行病学调查 ..... (180)
91. 国内 Crohn 病 1353 例综合分析 ..... (181)
92. 心理因素与溃疡性结肠炎 ..... (181)
93. 应用溃疡性结肠炎诊断与治疗标准的几点体会 (附 315 例溃疡性结肠炎结肠镜检查分析) ..... (181)
94. 重型溃疡性结肠炎临床特点回顾 ..... (181)
95. 78 例溃疡性结肠炎肠镜检查结果分析 ..... (181)
96. 31 例 Crohn 病的临床及实验室分析 ..... (181)
97. 儿童溃疡性结肠炎 8 例临床分析 ..... (181)
98. 小儿 Crohn 病 (附 3 例报告) ..... (181)
99. 肛周 Crohn 病 (附 3 例报告) ..... (181)
100. 消化道结核误诊为 Crohn 病分析——附 23 例报告 ..... (181)
101. 炎症性肠病 57 例诊治体会 ..... (181)
102. 结肠镜检查溃疡性结肠炎的体会 ..... (181)
103. 溃疡性结肠炎 26 例内镜分析 ..... (182)

104. 溃疡性结肠炎 36 例临床分析 .....	(182)
105. 23 例溃疡性结肠炎的临床分析 .....	(182)
106. 溃疡性结肠炎临床表现分析 .....	(182)
107. 纤维结肠镜对溃疡性结肠炎诊断作用 (附 36 例分析) .....	(182)
108. 22 例老年溃疡性结肠炎住院病人临床分析 .....	(182)
109. Crohn 病并发急性下消化道大出血 2 例报告 .....	(182)
110. Crohn 病致消化道大出血 5 例 .....	(182)
111. 溃疡性结肠炎血栓性并发症——附 2 例报道及文献复习 .....	(182)
112. 内镜下喷洒对氨水杨酸治疗溃疡性结肠炎 13 例疗效观察 .....	(182)
113. 西米替丁、庆大霉素、甲硝唑及 654-2 混合灌肠治疗溃疡性结肠炎临床疗效的分析 .....	(182)
114. 硫糖铝、甲硝唑、地塞米松治疗溃疡性结肠炎 .....	(182)
115. 56 例溃疡性结肠炎的临床治疗回顾 .....	(182)
116. 溃疡性结肠炎 40 例的治疗分析 .....	(183)
117. 丽珠肠乐治疗溃疡性结肠炎 29 例疗效观察 .....	(183)
118. 中西药结合保留灌肠治疗溃疡性结肠炎 20 例小结 .....	(183)
119. 溃疡性结肠炎的中西医结合治疗 75 例报告 .....	(183)
120. 中西医结合治疗 Crohn 病临床观察 .....	(183)
121. 中西医结合治疗溃疡性结肠炎——46 例临床分析 .....	(183)
122. 中西医结合治疗远端溃疡性结肠炎临床观察 (附 68 例分析) .....	(183)
123. 赛胃安、甲硝唑保留灌肠治疗溃疡性结肠炎 .....	(183)
124. 中药煎剂保留灌肠治疗溃疡性结肠炎 47 例 .....	(183)
125. 中药栓剂治疗溃疡性结肠炎临床效果观察 .....	(183)
126. 中西医结合治疗溃疡性结肠炎 47 例临床疗效分析 .....	(183)
127. 溃疡性结肠炎 20 例随访报告 .....	(183)

#### 第四章 综述与译文

1. 细胞因子在炎症肠病中的作用研究进展 .....	(184)
2. Th1 /Th2 淋巴细胞的检测及意义 .....	(189)
3. Fas /FasL 介导的细胞凋亡与几种胃肠疾病发病学关系的研究进展 .....	(195)
4. 肥大细胞在炎症性肠病中的作用 .....	(200)
5. 胃肠激素与炎症性肠病 .....	(205)
6. 炎症性肠病靶向治疗的新药——布地奈德 .....	(211)
7. 一种可重复的溃疡性结肠炎组织学分级标准 .....	(216)
8. 临床病理联系在结肠炎诊断中的重要性——结肠炎的临床病理分型 .....	(220)
9. 炎症性肠病的分类 .....	(228)

## 第五章 炎症性肠病诊断标准和治疗指南摘录

1. 炎症性肠病 (IBD) 的分类 .....	(233)
2. Crohn 病诊断标准摘录 .....	(233)
2.1 全国慢性非感染性肠道疾病学术研讨会标准 .....	(233)
2.2 日本消化系统疾病学会克隆病检讨委员会制定诊断标准 .....	(235)
2.3 日本厚生省特定疾患克隆病调查研究班制定诊断顺序 .....	(235)
2.4 Crohn 病 WHO 专家小组定义 .....	(236)
2.5 Crohn 病诊断要点 .....	(236)
2.6 美国 Crohn 病协作组 Crohn 病活动指数计算法 .....	(236)
2.7 美国《消化道病理学》关于 Crohn 病病理诊断的意见 .....	(237)
3. 溃疡性结肠炎诊断标准摘录 .....	(238)
3.1 全国消化疾病会议制定慢性非特异性溃疡性结肠炎的诊断标准 .....	(238)
3.2 全国慢性非感染肠道疾病学术研讨会制定溃疡性结肠炎的诊断及疗效标准 .....	(239)
3.3 日本制定的溃疡性结肠炎诊断标准 .....	(240)
3.4 溃疡性结肠炎病理、病程、病情程度分类 .....	(241)
3.5 溃疡性大肠炎 WHO 定义 .....	(241)
3.6 溃疡性大肠炎诊断标准 .....	(241)
3.7 美国《消化道病理学》标准 .....	(242)
4. 成人炎性肠病之诊断标准 .....	(243)
5. 成人 Crohn 病的治疗指南 .....	(247)
6. 溃疡性结肠炎诊治指南 .....	(253)
7. 炎症性肠病实践指南: 评价规范 .....	(256)

## 第六章 华西医科大学附一院 IBD 诊断标准和处理指南

1. 溃疡性结肠炎的诊断标准及疗效评价 .....	(263)
2. Crohn 病的诊断标准与疗效评价 .....	(265)
3. 溃疡性结肠炎处理指南 .....	(268)
4. Crohn 病处理指南 .....	(271)

# 第一章 国外专家讲演提纲

## 1. Causes and Mechanisms of Inflammatory Bowel Disease

**Claudio Fiocchi**

*Division of Gastroenterology*

*University Hospitals of Cleveland*

*Case Western Reserve University School of Medicine*

*Cleveland, Ohio, USA*

### Introduction

Intestinal inflammation is the most common reaction of the digestive system to infectious, immune, toxic, ischemic and other insults. Although the most frequent form of inflammation remains by far an acute self-limited response to infectious bacterial or viral agents, over the last half century there has been a significant and progressive increase of other types of inflammation. They are collectively named inflammatory bowel diseases (IBD), their cause is unknown, they are characteristically chronic and debilitating, and can lead to severe tissue destruction with an increased risk of bowel cancer. The two most common forms of IBD are ulcerative colitis and Crohn's disease, but additional types such as indeterminate, collagenous and lymphocytic colitis also exist. This review will provide a succinct overview of state-of-the-art knowledge on the etiology and pathogenesis of ulcerative colitis and Crohn's disease, and discuss its implication for the treatment of IBD. Whenever possible, some considerations will be included that might be specifically relevant to IBD in China.

### Environmental and Genetic Factors

The frequency of both forms of IBD has steadily increased over the last fifty years due to

a real increase of their incidence rather than an improvement in diagnostic modalities<sup>[1]</sup>. Interestingly, both forms of IBD first appeared in countries of high socioeconomic status, like Northern Europe and North America and subsequently in other parts of the world, including Southern and Western Europe, and more recently South America and Japan. This peculiar geographic distribution over time is believed to reflect subtle but important changes in environmental factors like diet, smoking and exposure to other still undefined elements. In Japan the increase of ulcerative colitis incidence after the Second World War was paralleled by an increased consumption of meat and dairy products<sup>[2]</sup>, but this alone is insufficient to conclude that a modification from a traditionally fish-based diet is responsible for IBD. Smoking is clearly linked to a worse outcome for Crohn's disease but, curiously, has a protective effect in ulcerative colitis<sup>[3]</sup>. An increased intestinal permeability has also been proposed as another factor predisposing to Crohn's disease, but if this is a true primary event or one secondary to subclinical inflammation remains to be determined<sup>[4]</sup>. It is difficult to explain the role of each factor, alone or in combination with others, but a unifying hypothesis is the increased cleanliness of the environment and less frequent exposure to pathogenic agents. This would cause the intestinal immune system not to be challenged early in childhood and become less capable to mount an effective immune response against pathogens later in life<sup>[5]</sup>.

Another important observation is that both Crohn's disease and ulcerative colitis are more common among first-degree relatives than expected by chance alone<sup>[6]</sup>. This could be due to exposure of all family members to the same environmental factors that predispose to IBD, but an alternative explanation is that the affected individuals share a common genetic background rendering them more susceptible to Crohn's disease or ulcerative colitis. This notion has stimulated an enormous interest in the investigation of genes linked to IBD and a large number of genetic associations and linkages have been reported<sup>[7]</sup>. At the moment it seems unlikely that a single gene or a limited set of genes will explain all IBD cases. It is more probable that multiple genes favor the appearance of IBD in different populations exposed to diverse environmental agents in each part of the world.

The trend of a progressive increase in the incidence of IBD is continuing, and countries like China are likely to see more and more cases of ulcerative colitis first and Crohn's disease later on, as it has previously observed in other countries. It would be of extreme importance to plan prospective epidemiological studies to track the evolution of IBD in China and potentially define the risk factors in the Chinese population.

## Microbial Factors

Since their recognition both ulcerative colitis and Crohn's disease were believed to have an infectious etiology because of their similarities to bacterial colitides like salmonellosis, shigellosis or amebic colitis. The IBD literature is full of studies that have searched for common or unusual bacteria, viruses and fungi, but no microbial agent has withstood the test of

time. During the last two decades attention has been focused on *Mycobacterium paratuberculosis*, an agent responsible for intestinal inflammation in cattle, and the measles virus as possible causes of Crohn's disease. However, direct recovery of either organism from affected tissues and indirect evidence of their presence by microbiological, immunological or molecular biological techniques have yielded negative or unconvincing results<sup>[8, 9]</sup>.

More recently a different view on the contribution of microbial agents to IBD is gaining increasing acceptance, e. g., that IBD, particularly Crohn's disease, is caused by an abnormal immune response against the normal autologous enteric flora<sup>[10]</sup>. Two lines of evidence support this view. The first comes from experimental models of IBD, where the majority of animals fail to develop colitis when placed in a germ-free environment. The second comes from a series of studies showing that cell-mediated and humoral immunity against bacterial antigens are enhanced in IBD patients<sup>[11]</sup>, bacterial stasis favor the development of IBD and fecal stream diversion prevents recurrence of Crohn's disease<sup>[12]</sup>, and the beneficial effect of antibiotics and probiotics in some IBD patients<sup>[13]</sup>. Taken together, these studies suggest that IBD may result from a loss of immune tolerance for the commensal flora. However, until the cause of IBD is found, the possibility that either ulcerative colitis or Crohn's disease are caused by infectious agents cannot be excluded.

## The Inflammatory Tissue Response

Even though knowledge of the factors predisposing to or causing ulcerative colitis and Crohn's disease is still incomplete, we have a good understanding of the cells, molecules and mechanisms responsible for chronic inflammation. The mucosal immune system is at the center of all aggressive and protective phenomena occurring in IBD from the very first clinical manifestations to the chronic stage of the disease, and its evolution into complications or remissions<sup>[14]</sup>. This is a complex and lengthy subject will be discussed in a simplified fashion. All branches of immunity are involved in IBD, with both quantitative and qualitative abnormalities. There is an excess of antibody production in IBD-involved intestine, but there is limited evidence that true antigen-specific autoantibodies play a significant role in tissue injury<sup>[15]</sup>. Other types of autoantibodies, such the pANCA, have some diagnostic value but they are not involved in mediating inflammation. A variety of functional abnormalities have been reported in regard to mucosal T-cell function which can be summarized as follows: in ulcerative colitis T-cells tend to be hyporeactive, while in Crohn's disease T-cells generally exhibit an enhanced effector function. There are enough data to suggest that Crohn's disease is a Th1-like response, whereas ulcerative colitis has some features of a Th2 response. In addition to classical immune cells, it is also clear that all other mucosal cells (epithelial, endothelial, mesenchymal and nerve cells) actively participate in inflammation, making IBD the outcome of a complex interplay of immune and non-immune interactions<sup>[16]</sup>.

Among the various components of gut inflammation most of the attention has been given

to substances locally secreted that modulate immune responses in the mucosal microenvironment. These include immunoregulatory cytokines such as interleukin (IL) -2, IL-4 and interferon-gamma, immunosuppressive cytokines like IL-10 and transforming growth factor-beta, proinflammatory cytokines like IL-1 beta, tumor necrosis factor (TNF) -alpha and IL-6, and chemokines that attract leukocytes into sites of inflammation, such as IL-8, macrophage chemotactic protein-1, and many others. Interest in these products is justified by the fact that their neutralization can effectively block inflammation and induce remission. In addition to cytokines and chemokines, various other molecules are also important, including growth factors and eicosanoids that can promote healing and cytoprotection, reactive oxygen metabolites and nitric oxide that can be toxic for gut tissue, and cell adhesion molecules that allow communication between different cell types and thus amplify inflammation. The investigation and understanding of how these different classes of molecules work in IBD has been instrumental for the development of rational and innovative therapies as discussed below.

## Lessons From Animal Models

During the last decades some of the most significant advances in the cause and mechanisms of IBD have derived from the study of animal models of IBD which allow experiments not feasible in humans and investigate the progress of inflammation over time. Several models have been developed, each with different characteristics, but their discussion is beyond the scope of this review. It is sufficient to state that none of them exactly reproduce all aspects of ulcerative colitis or Crohn's disease<sup>[17]</sup>, but these models have provided crucial new insights with direct implications for human disease. Such implications are summarized in the three following paragraphs:

1) Completely different and independent infectious, genetic or immune defects can cause gut inflammation, suggesting that different causes may trigger human IBD even though the overall clinical manifestations may be the same.

2) Most animal models fail to develop intestinal inflammation in a germ-free environment, indicating that the normal enteric flora is necessary to develop IBD. The same may be true in humans, but whether the whole flora or only selected components are involved is currently under investigation.

3) The animal's genetic background strongly influences the susceptibility and severity of IBD, indicating that although different genes may predispose humans to develop IBD, the type, location, clinical activity and final outcome may be dictated by the unique genetic make-up of each patient.

Finally, beside providing the above critical information, animal models have been instrumental in testing the efficacy of new drugs for IBD.

## Concluding Remarks and Therapeutic Implications

The ultimate reason to understand the cause and mechanisms of a disease is to be able to prevent the appearance of disease, eliminate the symptoms, establish a cure, and avoid recurrence. Unfortunately, we are far from this ideal situation, yet recent progress in the etiology and pathogenesis of IBD has been remarkable. This progress has resulted in a totally new approach to therapy resulting from our improved understanding of key mediators of inflammation. Based on this understanding trials are being performed injecting antibodies against anti-inflammatory cytokines like TNF- $\alpha$ <sup>[18]</sup> and adhesion molecules involved in migration of leukocytes into the bowel<sup>[19]</sup>, or administering cytokines with a natural anti-inflammatory activity like IL-10<sup>[20]</sup>. In addition to biologicals, the use of antibiotics and probiotics will probably become routine in the treatment of IBD<sup>[21]</sup>. Classical and still effective drugs, such as aminosalicylates and corticosteroids, will not be abandoned but rather combined with the new biologicals and enteric flora modulators, resulting in a more comprehensive and improved therapeutic outlook. Hopefully, all these new treatments will soon become available in China to provide the best possible treatment to local sufferers of ulcerative colitis and Crohn's disease.

## References

1. Ekblom A. Epidemiology of inflammatory bowel disease. In: Bistran BR, Walker-Smith JA, editors. *Inflammatory Bowel Diseases*. Basel: Karger; 1999. p. 7~21
2. Yoshida Y, Murata Y. Inflammatory bowel disease in Japan: studies of epidemiology and etiopathogenesis. *Med Clin North Am*, 1990; 74: 67~90
3. Rhodes J, Thomas GAO. Smoking: good or bad for inflammatory bowel disease? *Gastroenterology*, 1994; 106: 807~810
4. Hollander D. Permeability in Crohn's disease: altered barrier function in healthy relatives? *Gastroenterology*, 1993; 104: 1848~1851
5. Folkerts G, Walz G, Openshaw PJM. Do common childhood infections "teach" the immune system not to be allergic? *Immunol Today*, 2000; 21: 118~120
6. Lashner BA, Evans A, Kirsner JB, Hanauer SB. Prevalence and incidence of inflammatory bowel disease in family members. *Gastroenterology* 1986; 91: 1396~1400
7. van Heel DA, Sastangi J, Carey AH, Jewell DP. Inflammatory bowel disease: progress toward a gene. *Can J Gastroenterol* 2000; 14: 207~218
8. VanKruiningen HJ. Lack of support for a common etiology in Johne's disease of animals and Crohn's disease in humans. *Inflammatory Bowel Dis*, 1999; 5: 183~191
9. Ter Meulen V. Measles virus and Crohn's disease: view of a medical virologist. *Gut*, 1998; 43: 733~734
10. Sartor RB. Enteric microflora in IBD: pathogens or commensals? *Inflammatory Bowel Dis*, 1997; 3: 230~235



11. Rutgeerts P, Vermeire S. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. *Gastroenterology*, 1998; 115: 1006~1022
12. Janowitz HD. The role of the fecal stream in Crohn's disease: an historical and analytic perspective. *Inflammatory Bowel Dis*, 1998; 4: 29~39
13. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative? *Gastroenterology*, 1999; 116: 1246~1260
14. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. *Gastroenterology*, 1998; 115: 182~205
15. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease. New insights into autpimmune pathogenesis. *Dig Dis Sci*, 1999; 44: 1~13
16. Fiocchi C. Intestinal inflammation: a complex interplay of immune-non immune cell interactions. *Am J Physiol*, 1997; 273: G769~G775
17. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. *Gastroenterology*, 1995; 109: 1344~1367
18. Targan SR, Hanauer SB, vanDeventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. *N Engl J Med*, 1997; 337: 1029~1035
19. Hesterberg PE, Winsor-Hines D, Briskin MJ, Soler-Ferran D, Merrill C, MacKay CR, Newman W, Ringer DJ. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. *Gastroenterology*, 1996; 111: 1373~1380
20. VanDeventer SJH, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. *Gastroenterology*, 1997; 113: 383~389
21. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? *Inflammatory Bowel Dis*, 2000; 6: 107~115

## 炎症性肠病的病因和发病机制

美国俄亥俄州克利夫兰西余大学医学院克利夫兰大学医院胃肠科

Claudio Fiocchi 教授

肠道炎症是消化系统对感染、免疫、缺血和其他攻击因素最常见的反应。迄今为止,最常见的炎症仍是针对细菌或病毒感染的急性自限性反应。但是近半个世纪以来其他炎症已明显逐渐增多。他们被统称为炎症性肠病(IBD)。其病因尚不清楚,具有慢性和消耗性的特征,可导致结肠癌危险性增加的严重组织破坏。最常见的两种IBD是溃疡性结肠炎(UC)和Crohn病(CD),但也存在其他类型的IBD,如未定型结肠炎、胶原性和淋巴性结肠炎。本文将简略回顾有关UC和CD的病因和发病机制的最新知识,并讨论其对IBD治疗的意义。一旦可能,我们应进行一些特别与中国的IBD相关